nChroma Bio

formerly nChroma

nChroma

nChroma Bio is a biotech company in Boston, United States, founded in 2024. It has raised $470.0M across 4 rounds, most recently a $75.0M Venture Round in December 2024.

Employees
51–200
Founded
2024
Business Model
B2B
Total Funding
$470.0M
Last Round
$75.0M Venture RoundDec 2024
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 9 investors for this company. to use credits for reveals, or explore the API.

About

nChroma Bio is a clinical-stage genetic medicines company developing targeted in vivo delivery systems and engineered epigenetic silencers for durable disease treatment. Its lead program, CRMA-1001, is a liver-directed epigenetic therapy in Phase 1/2 trials targeting a functional cure for chronic hepatitis B. The company combines lipid nanoparticle delivery with proprietary epigenetic editing to achieve durable gene silencing without altering the underlying DNA sequence.

Funding History

Data from Indexed.vcUpdated
Venture RoundFinancingDec 2024
$75.0M

3 more funding events

  • Series B20233 investors
  • Series B20222 investors
  • Series A20212 investors

Funding: Series A through Venture Round. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Cloud/Infrastructure ×1
  • Engineering & DevOps ×1
  • Marketing & SEO ×1
  • Other ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech
Venture RoundTotal funding$884.0MJul 2025
Tessera Therapeutics

Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...

Somerville, United States201–500Biotech
Corporate RoundTotal funding$730.0MDec 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech
Private EquityTotal funding$647.0MFeb 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

nChroma Bio on Indexed.vc
<a href="https://indexed.vc/companies/nchroma-bio"><img src="https://indexed.vc/api/badge/company/nchroma-bio" alt="nChroma Bio on Indexed.vc" width="260" height="76" /></a>